Epithelial Mesenchymal Transition (EMT) in Metastatic Breast Cancer in Omani Women. 2017

Ritu Lakhtakia, and Adil Aljarrah, and Muhammad Furrukh, and Shyam S Ganguly
Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates. ritu.lakhtakia@mbru.ac.ae.

Breast cancer (BC) in Oman affects younger women and has a more aggressive course. Clinical and biological variables like age, pregnancy, tumor size, type, grade, receptor expression and proliferation predict disease aggression but there is no direct predictor of metastasis except lymphovascular invasion. Epithelial-mesenchymal transition (EMT) is characterized by epithelial cells losing epithelial and acquiring mesenchymal morpho-immunophenotypic characteristics. In tumors, EMT-like transitions may signify a metastatic phenotype and have features in common with cancer stem cells (CSC) which show resistance to chemotherapy. This study aimed to identify EMT and CSC phenotypes in metastatic and non-metastatic breast cancer in Omani women and their association with conventional clinico-pathological predictors of BC. In a retrospective study of ninety-six Omani women with breast cancer, the association of age, pregnancy/lactation, tumor size, type, grade, ductal carcinoma insitu (DCIS), lymphovascular invasion, hormone/ HER2 receptor expression and Ki67 proliferation index (Ki67 PI) was tested with EMT/ CSC phenotype and metastasis. Young age ≤ 40 years, lymphovascular invasion and EMT had a strong association with metastasis; CSC approached significance. Vimentin expression in tumor cells, fibronectin and MMP-11 in stroma were reliable markers of EMT; dual EMT and CSC phenotype (Vim+/ CD44+/ CD 24-/low) had a strong association with apocrine variant, basal-like tumors and triple negative cancers. EMT had a strong association with Ki67 proliferation index (PI) and CSC with HER2-like tumors and distant metastasis. These select markers may be useful in metastasis-prediction in pre-treatment biopsies.

UI MeSH Term Description Entries

Related Publications

Ritu Lakhtakia, and Adil Aljarrah, and Muhammad Furrukh, and Shyam S Ganguly
July 2023, International journal of molecular sciences,
Ritu Lakhtakia, and Adil Aljarrah, and Muhammad Furrukh, and Shyam S Ganguly
December 2023, Medical oncology (Northwood, London, England),
Ritu Lakhtakia, and Adil Aljarrah, and Muhammad Furrukh, and Shyam S Ganguly
January 2018, Advances in experimental medicine and biology,
Ritu Lakhtakia, and Adil Aljarrah, and Muhammad Furrukh, and Shyam S Ganguly
November 2023, Molecular and cellular biochemistry,
Ritu Lakhtakia, and Adil Aljarrah, and Muhammad Furrukh, and Shyam S Ganguly
May 2022, International journal of molecular sciences,
Ritu Lakhtakia, and Adil Aljarrah, and Muhammad Furrukh, and Shyam S Ganguly
January 2019, Archives of pharmacal research,
Ritu Lakhtakia, and Adil Aljarrah, and Muhammad Furrukh, and Shyam S Ganguly
October 2008, Developmental dynamics : an official publication of the American Association of Anatomists,
Ritu Lakhtakia, and Adil Aljarrah, and Muhammad Furrukh, and Shyam S Ganguly
April 2005, Cancer biology & therapy,
Ritu Lakhtakia, and Adil Aljarrah, and Muhammad Furrukh, and Shyam S Ganguly
October 2010, Annals of oncology : official journal of the European Society for Medical Oncology,
Ritu Lakhtakia, and Adil Aljarrah, and Muhammad Furrukh, and Shyam S Ganguly
May 2014, Oncogene,
Copied contents to your clipboard!